Click through for a guide to the phase 3 trials of IL-17A inhibitors in ankylosing spondylitis NICE has also expanded its recommendation for secukinumab use.

A quick-reference guide to the phase 3 trials of the IL-17A inhibitors secukinumab and ixekizumab in patients with psoriatic arthritis.

A meta-analysis of phase 3 trials indicates that IL-17A inhibitors have clinical efficacy for the treatment of ankylosing spondylitis, but at the cost of an increased risk for non-severe infections.

A meta-analysis of phase 3 trials indicates that IL-17A inhibitors have clinical efficacy for the treatment of ankylosing spondylitis, but at the cost of an increased risk for non-severe infections.

A quick-reference guide to the phase 3 trials of the IL-17A inhibitors secukinumab and ixekizumab in patients with psoriatic arthritis.

A quick-reference guide to the phase 3 trials of IL-17A inhibitors for the treatment of ankylosing spondylitis.

Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.

“There was a tendency for lower radiographic progression with [the] IL-17 inhibitor, which means it did at least as good as the well-established TNF blockers,” said Baraliakos At baseline, the mean mSASSS was 17.6 points and 16.5 points for the 287 and 286 patients taking secukinumab 150 mg and 300 mg, respectively, and 15.7 points for the 286 patients taking adalimumab biosimilar.

Therefore, they introduce a new treatment recommendation based on extramusculoskeletal manifestations, namely that tumor necrosis factor inhibitors are preferred in patients with a history of recurrent uveitis or active inflammatory bowel disease, whereas interleukin-17A inhibitors (IL-17i) are recommended in people with significant psoriasis.

Although trials of IL-23 inhibitors for the treatment of AS have failed to show benefit, the IL-17/IL-23 axis plays an important role in the onset and progression of AS; therefore, the IL-17/IL-23 axis may be targeted for AS treatment.

Measuring IL-22 levels may help predict whether IL-17 inhibitors or TNF inhibitors are more suitable for patients with psoriatic arthritis, Japanese research suggests.

Most patients with axial spondyloarthritis who stop taking ixekizumab respond to the treatment when it is reintroduced following disease flare, analysis of COAST-Y data suggests.

The IL-12/23 inhibitor is administered subcutaneously once every 12 weeks in children and adolescents aged 6–17 years, following loading doses at weeks 0 and 4, with dosing based on bodyweight.

Baraliakos and team report that the IL-17A/IL-17F inhibitor had sustained efficacy “following the rapid and clinically meaningful improvements within the first year of bimekizumab treatment.”

Summary of the phase 3 trials investigating the IL-17A/IL-17F inhibitor bimekizumab in patients with ankylosing spondylitis, nonradiographic axial spondyloarthritis, or psoriatic arthritis.

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials.

Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.

The results of two phase 3 studies suggest that dual inhibition of IL-17A and IL-17F with bimekizumab may represent a promising treatment option for nonradiographic axial spondyloarthritis and ankylosing spondylitis.

Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors (6:27).